Drug Recall: Vancomycin Injectable Lacks Sterility Assurance
Central Admixture Pharmacy Services recalls 7,632 bags of vancomycin injectable (NDC 71285-6078-1) nationwide due to FDA-identified sterility assurance deficiency.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a sterile injectable product. The recall addresses lack of assurance of sterility following FDA inspection, which presents a potential risk to patients receiving this medication. The score reflects the rubric criterion for risk-of-harm products where injury has not yet been reported, appropriate for Class II recalls lacking confirmed adverse events.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling 7,632 bags of vancomycin added to 0.9% sodium chloride injection (2 g/500 mL, 500 mL per bag) nationwide. The affected product carries NDC 71285-6078-1 and includes multiple lot numbers with various expiration dates between May and June 2023.
The recall was initiated because an FDA inspection called into question the sterility assurance of these products. Since vancomycin injectables are intended to be sterile, any uncertainty about sterility presents a potential risk to patients who receive this medication.
Healthcare professionals who have this product should stop using it immediately and contact the manufacturer for instructions on returning or disposing of the affected units.
The recalled product
- Product
- vancomycin added to 0.9% sodium chloride, 2 g/500 mL* (4 mg/mL), 500 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., 6580 Snowdrift Rd., Ste 100, Allentown, PA 18106, NDC 71285-6078-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Injectable Medication
- Hazard
- sterility-assurance
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot # 37-884151
- 37-884153
- Exp 05/03/2023
- 37-885670
- 37-885869
- 37-885900
- Exp 05/09/2023
- 37-886271
- Exp 05/11/2023
- 37-886857
- 37-886862
- 37-886865
- 37-886923
- Exp 05/15/2023
- 37-889190
- 37-889191
- Exp 05/23/2023
- 37-889596
- Exp 05/24/2023
- 37-890482
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27